Atea Pharmaceuticals, Inc.
AVIR
$3.65
$0.1153.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -60.17% | -42.48% | 26.34% | 10.32% | -62.36% |
| Gross Profit | 60.17% | 42.48% | -26.34% | -10.32% | 62.36% |
| SG&A Expenses | -25.78% | -22.68% | 15.85% | -12.38% | -7.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.92% | -44.07% | 22.15% | 0.99% | 20.89% |
| Operating Income | -16.92% | 44.07% | -22.15% | -0.99% | -20.89% |
| Income Before Tax | 8.25% | 45.87% | 14.16% | 6.06% | -44.20% |
| Income Tax Expenses | -14.81% | -12.12% | -35.53% | 2.26% | -3.19% |
| Earnings from Continuing Operations | 8.29% | 45.75% | 14.35% | 6.01% | -43.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.29% | 45.75% | 14.35% | 6.01% | -43.78% |
| EBIT | -16.92% | 44.07% | -22.15% | -0.99% | -20.89% |
| EBITDA | -16.97% | 44.14% | -22.23% | -0.99% | -20.96% |
| EPS Basic | 7.75% | 46.55% | 15.40% | 7.15% | -42.35% |
| Normalized Basic EPS | -29.40% | 46.67% | -38.24% | -6.96% | -29.53% |
| EPS Diluted | 7.75% | 46.55% | 15.40% | 7.15% | -42.35% |
| Normalized Diluted EPS | -29.40% | 46.67% | -38.24% | -6.96% | -29.53% |
| Average Basic Shares Outstanding | -0.60% | 1.48% | 1.23% | 1.23% | 1.02% |
| Average Diluted Shares Outstanding | -0.60% | 1.48% | 1.23% | 1.23% | 1.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |